Summary The prognostic role of epidermal growth factor receptor (EGFR) 
prognosis
Epidermal growth factor receptor (EGFR) is the protein product of the proto-oncogene HER-I. Ligand binding to the extracellular region of EGFR causes receptor dimerization. resultin, in autophosphorvlation and activation of cytoplasmic signal protein. which ultimateiy triggers DNA synthesis associated with proliferation and differentiation (Prigent and Lemoine. 1992 ). However. whether aberrant expression of EGFR is causally or consequently related to the development of cancer remains to be established. Some studies have reported EGFR to be of prognostic importance in lung cancer (Volm and Mattern. 1993. Volm et al. 1993 ): unfortunately. the relationship to sun-ival has been inconsistent (Pfeiffer et al. 1996a ).
Immunohistochemistry (IHC) is the most widely applied technique to assess expression of EGFR in patients with non-small-cell lung cancer (NSCLC) (Pfeiffer et al. 1996a ). Immunohistochemical results depend on the pnmary antibody. the visualization system and whether fixed or frozen tissues are used.
Furthermore. the evaluation of immunohistochemical slides is inherently qualitative or. at best. semiquantitative. The enzymelinked immunosorbent assay (ELISA) can quantify EGFR in cytosol extracts. We used a recently developed ELISA technique (Christensen et al. 1995) (Mountain. 1987) . No patient received post-operative adjuvant cytotoxic or radiation therapy. (Figure IA) . The patients were thus categorized as low (< 1.0 nmol EGFR g' protein), medium (1.0-2.0 nmol EGFR g' protein) or high (> 2.0 nmol EGFR g-' protein).
The distribution of EGFR.,, is shown in Figure iB ; the median EGFRH,c was 80%. EGFRELLsA and EGFR, results of paired samples from 190 patients with lung cancer are shown in Figure   2A . There was a highly significant correlation between EGFRI and EGFREJ,,A (r = 0.63, P < 0.001). The association between ELISA and IHC was improved even further (rs = 0.76) when the IHC score was used, i.e. when we also took into account the intensity of staining and relative tumour area ( Figure 2B) .
The association between EGFR expression and other variables was similar whether we used results obtained using ELISA or IHC.
We found expression of EGFR in all subtypes of NSCLC, but most frequently in squamous cell carcinomas (Table 1 We did not find any correlation between EGFR expression and survival in the entire group of patients with NSCLC (Figure 3 EGFR-binding characteristics were comparable in tumour and Folow-u time (years) normal lung tissue (Hwang et al, 1986; Veale et al, 1989; (Christensen et al, 1995 (Kaplan and Meier, 1958) and compared using the loghomogenized tissue sample consisting of tumour tissue intermixed -st (Peto et al, 1977) (Christensen et al, 1995) . JLTS Quantitation of EGFR has been reported in a few prior studies.
Veale et al (1993) (Stanton et al, 1994; Robertson et al, 1996) , but whether quantitative analysis will add to the prognostic significance of EGFR is doubtful. When we took into account the percentage of stained tumour cells, intensity of staining and cellularity, the correlation between ELISA and IHC was further improved. At least some of the remaining discrepancy may be due to intrumoral heterogeneity. To our knowledge, a detailed comparison of EGFR expression using ELISA and IHC has not been published previously, but some studies have determined the related growth factor receptor pl851ER-2 using NHC and ELISA (Dawkins et al, 1993; Dittadi et al, 1993; Nugent et al, 1994; Piffanelli et al, 1996) . In brief, the overall agreement was comparable with that of the present study.
In 
